1.

Current Developments in Molecular Monitoring in Chronic Myeloid Leukemia,

Therapeutic Advances in Hematology. 2016
2. The non-genomic loss of function of tumor suppressors: an essential role in
the pathogenesis of CML chronic phase BMC Cancer, 2016
3. Clinical significance of microRNAs in chronic and acute human leukemia,
Molecular Cancer, 2016
4. A novel BCR-ABL1 fusion gene identified by next-generation sequencing in
chronic myeloid leukemia, Molecular Cytogenetics, 2016
5. The Philadelphia chromosome in leukemogenesis, Chinese Journal of Cancer,
2016
6. What challenges remain in chronic myeloid leukemia research?
7. Tyrosine Kinase Inhibitors in Ph+ Chronic Myeloid Leukemia Therapy: A
review, Asian Pacific Journal of Cancer, 2016
8. Cytogenetic and molecular abnormalities in chronic myelomonocytic
leukemia, Blood Cancer Journal, 2016
9. New Developments in Chronic Myeloid Leukemia: Implications for Therapy,
Iran J Cancer, 2016
10.DNA Repair A Double-Edged Sword in the Genomic Stability of Cancer Cells
The case of Chronic Myeloid Leukemia, International Journal of Molecular
Sciences, 2015
11.Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Myeloid
Leukemia: Long-Term Patient Care and Management, J Adv Pract Oncology,
2016
12.Next Generation Sequencing identifies major DNA methylation changes
during progression of Ph+ chronic myeloid leukemia, Leukemia, 2016
13.Efficacy and Safety of Specific Inhibitor of the BCR-ABL1 Tyrosine Kinase in
Chronic Myeloid Leukemia, NEJM, 2001
14.Inhibition of Grb2 expression demonstrates an important role in BCR-ABLmediated MAPK activation and transformation of primary human
hematopoietic cells, Leukemia, 2011
15.Critical molecular pathways in cancer stem cells of CML, Leukemia, 2010
16.Practical Advice for Determining the Role of the BCR-ABL Mutations in Guiding
Tyrosine Kinase Inhibitor Therapy in Patients With CML, Cancer, 2011
17.BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogenous
leukemia, Leukemia, 2010
18.MiRNA as Biomarkers in Chronic Myelogenous Leukemia, Drug Dev Res, 2016
19.Programmed cell death 4 and BCR-ABL fusion gene expression ar enegatively
correlated in chronic myeloid leukemia, Oncology Letters, 2016
20.Role of tyrosine-kinase inhibitors in myeloproliferatice neoplasms:
comparative lessons learned, OncoTargets and Therapy, 2016
21.The impact of next generation sequencing technologies on hematological
research a review, Pathogenesis Journal, 2015
22.Novel Drug Therapies in myeloid leukemia
23.Senzitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in
CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Patients Is Associated with Imatinib Resistance: Implications in the PostImatinib Era, PLOS, 2013

24.BCR-ABL Mutations in Chronic Myeloid Leukemia Patients with Failure and

Warning to First and Second-Line Tyrosine Kinase Inhibitor Therapy: What Is
the Advantage of Next-Generation Sequencing over Conventional
Sequencing?, Blood Journal, 2015
25.Next-generation sequencing for senzitive detection of BCR-ABL1 mutations
relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients,
Oncotarget, 2016
26.MicroRNAs mediated regulation of MAPK signaling pathways in CML,
Oncotarget, 2016
27.The new challenge in oncology: Next-generation sequencing and its
application in precision medicine, Anales de Pediatria, 2016
28.Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by
ultra-deep sequencing of the BCR-ABL kinase domain, Bloog Journal, 2014
29.http://www.bloodjournal.org/content/126/23/346?sso-checked=true&trendmdshared=0
30.http://www.bloodjournal.org/content/122/21/380.short?ssochecked=true&trendmd-shared=0
31.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548169/
32.http://www.bloodjournal.org/content/122/21/384?sso-checked=true